Bioretec Oy
OMXH:BRETEC
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.82
2.94
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Bioretec Oy
Cash & Cash Equivalents
Bioretec Oy
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bioretec Oy
OMXH:BRETEC
|
Cash & Cash Equivalents
€6.9m
|
CAGR 3-Years
45%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
R
|
Revenio Group Oyj
OMXH:REG1V
|
Cash & Cash Equivalents
€13.5m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
19%
|
|
|
M
|
Modulight Oyj
OMXH:MODU
|
Cash & Cash Equivalents
€409k
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
O
|
Optomed Oyj
OMXH:OPTOMED
|
Cash & Cash Equivalents
€7.1m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
N
|
Nexstim Oyj
OMXH:NXTMH
|
Cash & Cash Equivalents
€3m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
B
|
Biohit Oyj
OMXH:BIOBV
|
Cash & Cash Equivalents
€1.8m
|
CAGR 3-Years
22%
|
CAGR 5-Years
7%
|
CAGR 10-Years
20%
|
|
Bioretec Oy
Glance View
Bioretec Ltd. develops bioabsorbable and bioresorbable implants for pediatric and adult orthopaedics. The company is headquartered in Tampere, Lansi-Suomen. The company went IPO on 2021-09-28. The firm operates as a developer, manufacturer and commercializer of innovative bioresorbable orthopedic implants and implant materials used for the treatment of bone and soft tissue injuries. Bioretec Oy’s existing Activa product portfolio consists of bioabsorbable biopolymer products that are alreadyavailable in the market for applications in pediatrics, trauma surgery as well as sports surgery. Bioretec Oy has one Germany-based subsidiary, BRI.Tech GmbH. The Company’s products are used all over the world.
See Also
What is Bioretec Oy's Cash & Cash Equivalents?
Cash & Cash Equivalents
6.9m
EUR
Based on the financial report for Dec 31, 2023, Bioretec Oy's Cash & Cash Equivalents amounts to 6.9m EUR.
What is Bioretec Oy's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
41%
Over the last year, the Cash & Cash Equivalents growth was 465%. The average annual Cash & Cash Equivalents growth rates for Bioretec Oy have been 45% over the past three years , 41% over the past five years .
You don't have any saved screeners yet
